• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心力衰竭和慢性肾脏病的表现与2型糖尿病早期死亡风险增加相关:基于日本真实世界医院理赔数据库的分析

Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type 2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims Database.

作者信息

Kadowaki Takashi, Komuro Issei, Morita Naru, Akiyama Hiroki, Kidani Yoko, Yajima Toshitaka

机构信息

Toranomon Hospital, Tokyo, Japan.

Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.

出版信息

Diabetes Ther. 2022 Feb;13(2):275-286. doi: 10.1007/s13300-021-01191-y. Epub 2022 Jan 10.

DOI:10.1007/s13300-021-01191-y
PMID:35006534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8873323/
Abstract

INTRODUCTION

To assess the initial manifestation of comorbidities and their impact on mortality risk in patients with type 2 diabetes mellitus (T2DM) without a history of cardiovascular or renal complications (i.e., in the early stages of T2DM) compared with patients without T2DM.

METHODS

We performed a retrospective cohort study using a Japanese hospital claims database. The incidence rates of comorbidities (chronic kidney disease [CKD], heart failure [HF], myocardial infarction [MI], peripheral arterial disease [PAD], and stroke) and mortality risk were compared between patients with T2DM and age-/sex-matched patients without T2DM (matched 1:2).

RESULTS

Among the comorbidities assessed in this study, CKD and/or HF was the most frequent initial manifestation in the patients with T2DM (n = 426,186) with an incidence rate 2.02 times greater than that in matched patients without T2DM (n = 1,018,609). The mortality risk was also greater in patients with T2DM than in patients without T2DM with a hazard ratio of 1.73. In both patients with and without T2DM, the presence of CKD or HF was associated with greater mortality risks compared with the presence of MI, PAD, or stroke.

CONCLUSIONS

The high incidence of CKD or HF manifestation can contribute to the augmented mortality risk in patients in the early stages of T2DM compared with patients without T2DM. These findings highlight the importance of early interventions for preventing/treating CKD and HF to improve the prognosis of patients with T2DM.

摘要

引言

评估2型糖尿病(T2DM)且无心血管或肾脏并发症病史(即T2DM早期阶段)的患者中合并症的初始表现及其对死亡风险的影响,并与无T2DM的患者进行比较。

方法

我们使用日本医院理赔数据库进行了一项回顾性队列研究。比较了T2DM患者与年龄和性别匹配的无T2DM患者(匹配比例为1:2)的合并症(慢性肾脏病[CKD]、心力衰竭[HF]、心肌梗死[MI]、外周动脉疾病[PAD]和中风)发病率及死亡风险。

结果

在本研究评估的合并症中,CKD和/或HF是T2DM患者(n = 426,186)最常见的初始表现,其发病率比匹配的无T2DM患者(n = 1,018,609)高2.02倍。T2DM患者的死亡风险也高于无T2DM的患者,风险比为1.73。在有和无T2DM的患者中,与存在MI、PAD或中风相比,存在CKD或HF与更高的死亡风险相关。

结论

与无T2DM的患者相比,CKD或HF表现的高发生率可能导致T2DM早期患者的死亡风险增加。这些发现凸显了早期干预预防/治疗CKD和HF以改善T2DM患者预后的重要性。

相似文献

1
Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type 2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims Database.心力衰竭和慢性肾脏病的表现与2型糖尿病早期死亡风险增加相关:基于日本真实世界医院理赔数据库的分析
Diabetes Ther. 2022 Feb;13(2):275-286. doi: 10.1007/s13300-021-01191-y. Epub 2022 Jan 10.
2
Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database.2 型糖尿病患者的心血管和肾脏疾病:首次发病表现和住院费用的 5 年累积发生率:法国全国索赔数据库 SNDS 中的一个队列。
Cardiovasc Diabetol. 2024 Jan 9;23(1):22. doi: 10.1186/s12933-023-02101-1.
3
Epidemiology and resource use in Spanish type 2 diabetes patients without previous cardiorenal disease: CaReMe Spain study summary.西班牙无既往心肾疾病 2 型糖尿病患者的流行病学和资源利用:CaReMe Spain 研究总结。
Endocrinol Diabetes Nutr (Engl Ed). 2022 Aug-Sep;69(7):509-519. doi: 10.1016/j.endien.2022.07.005.
4
Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.心脏-肾脏-代谢合并症对 2 型糖尿病患者心血管结局和死亡率的影响。
Am J Nephrol. 2020;51(1):74-82. doi: 10.1159/000504558. Epub 2019 Dec 6.
5
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.2 型糖尿病患者心力衰竭和慢性肾脏病表现与死亡风险的相关性:一项大型跨国队列研究。
Diabetes Obes Metab. 2020 Sep;22(9):1607-1618. doi: 10.1111/dom.14074. Epub 2020 Jun 3.
6
Machine learning models for prediction of HF and CKD development in early-stage type 2 diabetes patients.机器学习模型预测早期 2 型糖尿病患者心衰和慢性肾脏病的发生。
Sci Rep. 2022 Nov 21;12(1):20012. doi: 10.1038/s41598-022-24562-2.
7
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.钠-葡萄糖共转运蛋白 2 抑制剂在无心血管和肾脏疾病的日本 2 型糖尿病患者中的使用与较低的心衰和慢性肾脏疾病风险相关。
Diabetes Obes Metab. 2021 Apr;23 Suppl 2:19-27. doi: 10.1111/dom.14119.
8
The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia.2型糖尿病患者中心血管疾病、慢性肾病和肥胖症的患病率及联合治疗情况:沙特阿拉伯的一项双中心回顾性横断面研究
Saudi Pharm J. 2024 May;32(5):102054. doi: 10.1016/j.jsps.2024.102054. Epub 2024 Mar 28.
9
Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.评估 2 型糖尿病、既往心血管疾病以及两者兼有患者未来心血管事件风险、医疗资源利用和成本。
Curr Med Res Opin. 2020 Dec;36(12):1927-1938. doi: 10.1080/03007995.2020.1832455. Epub 2020 Nov 2.
10
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.与 2 型糖尿病患者心血管和肾脏疾病事件相关的医疗保健利用成本:一项跨越 12 个国家的多国观察性研究。
Diabetes Obes Metab. 2022 Jul;24(7):1277-1287. doi: 10.1111/dom.14698. Epub 2022 Apr 19.

引用本文的文献

1
Heterogeneity in the development of diabetes-related complications: narrative review of the roles of ancestry and geographical determinants.糖尿病相关并发症发展的异质性:关于血统和地理决定因素作用的叙述性综述
Diabetologia. 2025 Jul 22. doi: 10.1007/s00125-025-06482-8.
2
Reducing the Burden of Heart Failure in Japan With Dapagliflozin - A Cost Offset Model (IMPLICATION HF).达格列净减轻日本心力衰竭负担——成本抵消模型(IMPLICATION HF)
Circ Rep. 2025 Apr 12;7(6):426-432. doi: 10.1253/circrep.CR-25-0022. eCollection 2025 Jun 10.
3
Control of Mitochondrial Quality: A Promising Target for Diabetic Kidney Disease Treatment.

本文引用的文献

1
Diabetic kidney disease; review of the current knowledge.糖尿病肾病;当前知识综述
J Renal Inj Prev. 2013 Jun 1;2(2):73-80. doi: 10.12861/jrip.2013.24. eCollection 2013.
线粒体质量控制:糖尿病肾病治疗的一个有前景的靶点。
Kidney Int Rep. 2024 Dec 31;10(4):994-1010. doi: 10.1016/j.ekir.2024.12.029. eCollection 2025 Apr.
4
Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies.基于日本研究数据的SGLT2抑制剂治疗心肾代谢疾病的成本效益分析。
Adv Ther. 2025 Jun;42(6):2888-2905. doi: 10.1007/s12325-025-03157-z. Epub 2025 Apr 29.
5
Emerging New Era of Artificial Intelligence and Digital Medicine-directed Management of Chronic Kidney Disease.人工智能与数字医学导向的慢性肾脏病管理的崭新时代
JMA J. 2025 Jan 15;8(1):57-59. doi: 10.31662/jmaj.2024-0221. Epub 2024 Sep 20.
6
Influence of Functional Impairment on Prognosis in Hospitalized Elderly Patients on Dialysis.功能障碍对老年住院透析患者预后的影响。
JMA J. 2023 Oct 16;6(4):414-415. doi: 10.31662/jmaj.2023-0104. Epub 2023 Sep 29.
7
Cystacin C-based eGFR and Creatinine Clearance-based eGFR in Patients with Severe Motor and Intellectual Disabilities.重度运动和智力残疾患者中基于胱抑素C的估算肾小球滤过率和基于肌酐清除率的估算肾小球滤过率
JMA J. 2023 Oct 16;6(4):487-488. doi: 10.31662/jmaj.2023-0137. Epub 2023 Oct 4.
8
Esaxerenone for nocturnal hypertension and possible future direction for treatment of hypertension-cardiovascular-kidney comorbidity.依普利酮治疗夜间高血压及高血压-心血管-肾脏共病未来可能的治疗方向。
Hypertens Res. 2023 Aug;46(8):2059-2061. doi: 10.1038/s41440-023-01338-3. Epub 2023 Jun 16.
9
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.钠-葡萄糖共转运蛋白 2 抑制剂:从降糖药物到治疗心血管肾代谢综合征的关键药物。
Front Endocrinol (Lausanne). 2023 Jan 30;14:1111984. doi: 10.3389/fendo.2023.1111984. eCollection 2023.
10
Machine learning models for prediction of HF and CKD development in early-stage type 2 diabetes patients.机器学习模型预测早期 2 型糖尿病患者心衰和慢性肾脏病的发生。
Sci Rep. 2022 Nov 21;12(1):20012. doi: 10.1038/s41598-022-24562-2.